Cleerly LABS vs CAC Software
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if you require a comprehensive, AI-powered analysis of coronary CT angiography (CCTA) to go beyond simple calcification scores. This tool is ideal for detailed characterization of plaque volume and type, detection of stenosis, and assessment of potential ischemia, enabling personalized heart disease management and tracking disease progression over time.
View Cleerly LABS →Choose CAC Software if…
Choose Imbio's CAC Software if your primary need is automated, rapid quantification of coronary artery calcification from non-contrast chest CT scans. This tool is best suited for initial risk stratification of coronary artery disease by providing Agatston scores and other calcification metrics, integrating seamlessly into existing DICOM viewing workflows without requiring a dedicated CCTA.
View CAC Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | CAC Software |
|---|---|---|
| Pricing | Per analysis | Unknown |
| Deployment | Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer. | Cloud-based (SaaS), integrates with PACS |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CAC SoftwareImbio CAC Software emphasizes fully automated processing with minimal user intervention and direct integration into existing DICOM workflows, which streamlines the radiologist's experience. Cleerly LABS is web-based and offers comprehensive analysis, but the 'Cleerly Proxy for data transfer' might introduce a slightly more involved setup compared to Imbio's seamless DICOM integration.
Clinical Value
Cleerly LABSCleerly LABS provides a significantly more comprehensive assessment by characterizing plaque volume and type, detecting and quantifying stenosis, and offering ischemia detection with its module, allowing for personalized heart disease management and tracking progression over time. Imbio CAC Software, while valuable for quantifying coronary artery calcification, offers a narrower scope focused primarily on calcification burden and risk assessment.
Pricing & Value
Cleerly LABSCleerly LABS provides transparent pricing information, including a retail price and a discounted offer, allowing potential users to understand the direct cost per analysis. In contrast, Imbio CAC Software requires contacting them for pricing, which makes it impossible to assess its value without further inquiry.
Enterprise Readiness
CAC SoftwareImbio CAC Software offers greater deployment flexibility with options for Cloud, On-premise, or Partner platforms, which can be crucial for enterprises with varying IT infrastructure and data governance requirements. Both tools are FDA-cleared, HIPAA compliant, and integrate with existing clinical workflows, but Imbio's broader deployment choices give it an edge in enterprise adaptability.
Innovation
Cleerly LABSCleerly LABS demonstrates higher innovation by offering a comprehensive AI-driven analysis of CCTA that includes detailed plaque characterization (volume, type), stenosis quantification, and the ability to track disease progression and detect ischemia. Imbio CAC Software, while utilizing deep learning for automated calcification quantification, addresses a more focused and established aspect of cardiovascular risk assessment.
Support & Docs
TieBoth companies offer clear channels for support, including online forms, email, and phone contact during business hours. While Imbio explicitly mentions contacting support for user manuals, Cleerly also implies documentation through its 'Client Support' for existing users. Neither tool's documentation or support offerings stand out significantly above the other based on the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | CAC Software |
|---|---|---|
| Name | Cleerly LABS | CAC Software |
| Company | Cleerly | Imbio |
| Description | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | Automated image post-processing algorithms designed to help radiologists and cardiologists determine the location and calculate the amount of calcification within the coronary arteries in patients who have undergone a non-contrast, chest computed tomography (CT). |
| Primary Imaging Modality | Coronary CT Angiography (CCTA) | Non-contrast, chest computed tomography (CT) |
| Key Feature: Atherosclerosis/Plaque Characterization | Comprehensive coronary plaque assessment (volume, type) | Not specified |
| Key Feature: Stenosis Detection | Stenosis detection and quantification | Not specified |
| Key Feature: Calcification Quantification | Not specified | Quantification of calcification within coronary arteries; Outputs Agatston score, arterial age, calcified lesion mass and volume |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and CAC Software.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or CAC Software
Backers
Who funded each tool's parent company.